Targets › CD276
13 programs from 12 companies in 35 trials: 23 Phase 1, 8 Phase 2, 4 Phase 3; Oncology; next expected readout Dec 2026.
May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. (UniProt, Q5ZPR3)
Open in Phaseline: the race on CD276, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hansoh BioMedical R&D Company | HS-20093 anti-B7-H3 antibody-drug conjugate | B7H3, CD276 | Phase 3 | Osteosarcoma; Small Cell Lung Cancer; Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| GSK | Risvutatug Rezetecan (GSK5764227) anti-B7-H3 antibody-drug conjugate | TROP2, CD276 | Phase 3 | Neoplasms, Lung; Neoplasms, Prostate; Neoplasms; Gastrointestinal Neoplasms | Aug 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Enoblituzumab CD276 antigen cross-linking agent | CD276 | Phase 2 | Prostate Cancer | Jul 2027 |
| Pediatric Brain Tumor Consortium | 131I-Omburtamab Radiolabeled anti-B7-H3 (CD276) monoclonal antibody for targeted radioimmunotherapy | CD276 | Phase 2 | Recurrent Medulloblastoma | Sep 2027 |
| University Health Network, Toronto | GSK5764227 Anti-B7-H3 antibody-drug conjugate | CD276 | Phase 2 | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Jun 2030 |
| Beijing Tiantan Hospital | TX103-CAR-T Cell Injection anti-B7-H3 CAR-T cell therapy | CD276 | Phase 1 | Glioblastoma | Dec 2026 |
| Beijing Biotech | EB-G3B7-NK dual-target CAR-NK cells Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr | CD276, MSLN, EGFR, ERBB2, IL13RA2 | Phase 1 | Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) … | Feb 2027 |
| Beijing Biotech | EB-DTNB-NK Dual-target GD2/B7-H3 CAR-NK cells with IL-15 support and inducible safety switch | GYPC, CD276 | Phase 1 | Relapsed Neuroblastoma | Mar 2027 |
| German Cancer Research Center | CC-3 Bispecific CD276xCD3 antibody | CD276, CD3E | Phase 1 | Colorectal Cancer | Mar 2027 |
| National Cancer Institute (NCI) | Autologous B7-H3 CAR T anti-B7-H3 chimeric antigen receptor T cell therapy | CD276 | Phase 1 | Recurrent Small Cell Lung Cancer | Jan 2030 |
| UNC Lineberger Comprehensive Cancer Center | CAR.B7-H3T cells Anti-B7-H3 CAR-T cells | CD276 | Phase 1 | Glioblastoma Multiforme | May 2030 |
| Myricx Pharma | MX006 Anti-B7-H3 antibody-drug conjugate | CD276 | Phase 1 | Advanced and/or Metastatic Solid Tumors Known to Express B7-H3 | Jul 2030 |
| Innolake Biopharm | ILB-3101 B7-H3-targeting antibody-drug conjugate | CD276 | Phase 1 | Advanced Solid Tumor | – |
Advanced Solid Tumor (3) Non-Small Cell Lung Cancer (3) Osteosarcoma (2) Glioblastoma (2) Neoplasms, Lung (2) Neoplasms (2) Prostate Cancer (2) Small Cell Lung Cancer (1) Head and Neck Squamous Cell Carcinoma (1) Advanced Solid Tumors (1) Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (1) Metastatic Colorectal Cancer (CRC) (1)
mixed (5), antibody (3), other (2), small molecule (2), protein or peptide (1)
Beijing Biotech (2) Hansoh BioMedical R&D Company (1) Beijing Tiantan Hospital (1) Pediatric Brain Tumor Consortium (1) Innolake Biopharm (1) Myricx Pharma (1) University Health Network, Toronto (1) GSK (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) German Cancer Research Center (1) UNC Lineberger Comprehensive Cancer Center (1) National Cancer Institute (NCI) (1)
B7H3 (1) TROP2 (1) CD3E (1) MSLN (1) EGFR (1) ERBB2 (1) IL13RA2 (1) GYPC (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.